Invention Grant
- Patent Title: Neridronic acid for treating arthritis
-
Application No.: US15840066Application Date: 2017-12-13
-
Publication No.: US10039773B2Publication Date: 2018-08-07
- Inventor: Herriot Tabuteau
- Applicant: ANTECIP BIOVENTURES II LLC
- Applicant Address: US NY New York
- Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee: ANTECIP BIOVENTURES II LLC
- Current Assignee Address: US NY New York
- Agency: Maschoff Brennan Laycock Gilmore
- Agent Brent A. Johnson; Yuefen Zhou
- Main IPC: A61K31/66
- IPC: A61K31/66 ; A61K31/663 ; A61K31/573 ; A61K9/00 ; A61K45/06 ; A61K9/20 ; A61K31/675
Abstract:
Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.
Public/Granted literature
- US20180110789A1 OSTEOCLAST INHIBITORS FOR KNEE CONDITIONS Public/Granted day:2018-04-26
Information query
